SCHEMBL725752

SCHEMBL725752

NCCOCCOCCC=O

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9952291 1.00 HIF1A (0.32) HIF1A
SCHEMBL14873888 1.00 HIF1A (0.32) HIF1A
SCHEMBL20169646 1.00 HIF1A (0.32) HIF1A
SCHEMBL16329660 1.00 HIF1A (0.32) HIF1A
SCHEMBL15773944 1.00 HIF1A (0.32) HIF1A
SCHEMBL1397641 1.00 HIF1A (0.32) HIF1A
SCHEMBL16329771 1.00 HIF1A (0.32) HIF1A
SCHEMBL16692019 0.97
SCHEMBL16329560 0.93
SCHEMBL23130636 0.86 HIF1A (0.41) HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230372508-A1 LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES OLIX US, INC. 2023-11-23 US claimed
WO-2023225650-A1 LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES OLIX US, INC. (US) 2023-11-23 WO claimed
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 US claimed
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Modema Therapeutics, Inc. (US) 2017-05-18 US claimed
US-20150038435-A1 N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF NOVO NORDISK A/S (DK) 2015-02-05 US claimed
EP-2820150-A1 N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF Novo Nordisk A/S (DK) 2015-01-07 EP claimed
WO-2013128003-A1 N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF NOVO NORDISK A/S (DK) 2013-09-06 WO claimed
US-20240239852-A1 AMYLIN RECEPTOR AGONISTS NOVO NORDISK A/S (DK) 2024-07-18 US disclosed
WO-2024133160-A1 HEPATITIS B COMPOSITIONS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-06-27 WO disclosed
EP-4387597-A1 FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF GlaxoSmithKline Biologicals SA (BE) 2024-06-26 EP disclosed
EP-4387596-A1 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME GlaxoSmithKline Biologicals SA (BE) 2024-06-26 EP disclosed
WO-2024113009-A1 AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY THE UNIVERSITY OF QUEENSLAND (AU) 2024-06-06 WO disclosed
US-20240173400-A1 HERPES SIMPLEX VIRUS VACCINE MODERNATX, INC. (US) 2024-05-30 US disclosed
US-20110293714-A1 PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES NOVO NORDISK A/S (DK) 2011-12-01 US disclosed
EP-2370059-A1 PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES Novo Nordisk A/S (DK) 2011-10-05 EP disclosed
US-20110105720-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK A/S (DK) 2011-05-05 US disclosed
EP-2254906-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES Novo Nordisk A/S (DK) 2010-12-01 EP disclosed
WO-2010060667-A1 PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES NOVO NORDISK A/S (DK) 2010-06-03 WO disclosed
WO-2009115469-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK A/S (DK) 2009-09-24 WO disclosed
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED (IE) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105720-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE HIF1A 1903/4885
US-20240173400-A1 HERPES SIMPLEX VIRUS VACCINE STING1, RPL23, RPL17 HIF1A 2127/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 HIF1A 1292/4885
US-20110293714-A1 PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES IAPP, VIP, INSR HIF1A 3570/4885
US-20230372508-A1 LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES DNPEP, LNPEP, FGB HIF1A 1830/4885
US-20150038435-A1 N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF NGLY1, PTMS, VIP HIF1A 3088/4885
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS GLP1R, GIPR, GCGR HIF1A 1106/4885
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 HIF1A 1292/4885
US-20240239852-A1 AMYLIN RECEPTOR AGONISTS GLP1R, GPR119, GIPR HIF1A 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.